The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Prognostic significance of t(11;14) in multiple myeloma
Susan Bal, MD, MBBS, O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, shares the findings of a real-world investigation into the characteristics and outcomes of t(11;14) multiple myeloma patients. Progression-free survival (PFS) and overall survival (OS) were compared for t(11;14)+ and t(11;14)- patients, as well as other common genetically-defined subgroups. The analysis found that patients with t(11;14)+ had a worse PFS and OS compared to patients with t(11;14)-. The presence of the t(11;14) translocation also negatively impacted prognosis in myeloma with del(17p). This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
